Cargando…
An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645462/ http://dx.doi.org/10.1186/2051-1426-3-S2-P154 |
| _version_ | 1782400817998856192 |
|---|---|
| author | Hellmann, Matthew Ramalingam, Suresh Reck, Martin O'Byrne, Ken Paz-Ares, Luis Harbison, Christopher T Bhagavatheeswaran, Prabhu Nathan, Faith Brahmer, Julie |
| author_facet | Hellmann, Matthew Ramalingam, Suresh Reck, Martin O'Byrne, Ken Paz-Ares, Luis Harbison, Christopher T Bhagavatheeswaran, Prabhu Nathan, Faith Brahmer, Julie |
| author_sort | Hellmann, Matthew |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645462 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46454622015-11-20 An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) Hellmann, Matthew Ramalingam, Suresh Reck, Martin O'Byrne, Ken Paz-Ares, Luis Harbison, Christopher T Bhagavatheeswaran, Prabhu Nathan, Faith Brahmer, Julie J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645462/ http://dx.doi.org/10.1186/2051-1426-3-S2-P154 Text en Copyright © 2015 Hellmann et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Hellmann, Matthew Ramalingam, Suresh Reck, Martin O'Byrne, Ken Paz-Ares, Luis Harbison, Christopher T Bhagavatheeswaran, Prabhu Nathan, Faith Brahmer, Julie An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) |
| title | An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) |
| title_full | An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) |
| title_fullStr | An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) |
| title_full_unstemmed | An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) |
| title_short | An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) |
| title_sort | open label randomized phase iii trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (pt-dc) in patients with chemotherapy-naïve stage iv or recurrent non-small cell lung cancer (nsclc) (checkmate 227) |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645462/ http://dx.doi.org/10.1186/2051-1426-3-S2-P154 |
| work_keys_str_mv | AT hellmannmatthew anopenlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT ramalingamsuresh anopenlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT reckmartin anopenlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT obyrneken anopenlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT pazaresluis anopenlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT harbisonchristophert anopenlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT bhagavatheeswaranprabhu anopenlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT nathanfaith anopenlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT brahmerjulie anopenlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT hellmannmatthew openlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT ramalingamsuresh openlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT reckmartin openlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT obyrneken openlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT pazaresluis openlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT harbisonchristophert openlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT bhagavatheeswaranprabhu openlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT nathanfaith openlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 AT brahmerjulie openlabelrandomizedphaseiiitrialofnivolumabornivolumabplusipilimumabvsplatinumdoubletchemotherapyptdcinpatientswithchemotherapynaivestageivorrecurrentnonsmallcelllungcancernsclccheckmate227 |